Si bone inc   (SIBN)

SI-BONE, Inc. Surpasses Expectations with Record-Breaking Financial Results

Innovative Medical Device Company Sees Dramatic Revenue Growth Amidst Challenging Market Conditions

Published Feb 28 2024 / Modified Feb 28 2024
CSIMarket Team / CSIMarket.com

Medical_ultrasound_examination_pdSI-BONE, Inc., a leading medical device company specializing in musculoskeletal disorders of the sacropelvic anatomy, has recently announced its financial results for the fourth quarter and full year ended December 31, 2023.
The company reported an improvement in its earnings per share (EPS) compared to the previous year, with a decrease in loss per share from $-0.31 to $-0.24.
Additionally, the company saw a sequential improvement in EPS from $-0.25 in the preceding financial reporting period.

One of the highlights of SI-BONE's financial performance was the significant increase in revenue.
The company experienced a rapid revenue growth of 21.278%, with revenues reaching $38.75 million in the fourth quarter of 2023 compared to $31.95 million in the same period a year ago.
Furthermore, the company's revenue also increased by 14.067% sequentially from $33.97 million.

SI-BONE's impressive revenue growth sets it apart from its industry peers in the Medical Equipment & Supplies sector, which reported a 8.27% rise in revenue during the same period.
This achievement demonstrates the company's ability to outperform its competitors in terms of top-line growth.

In terms of net shortfall, SI-BONE reported a decrease in the fourth quarter of 2023, with a net loss of $-10.983 million compared to a deficit of $-11.175 million in the same financial reporting period a year ago.
This improvement in net shortfall reflects the company's efforts to manage its financial performance effectively.

Notably, the company's inventories have declined to $20.2 million from the previous quarter, although it still represents an increase relative to the same period a year ago.
Additionally, SI-BONE's accounts receivable have increased, indicating rising demand for its products.
Accounts receivables were valued at $22.0 million, showing growth compared to the preceding quarter.

Looking ahead, SI-BONE is expected to announce its next financial results on March 1, 2024.
Investors can anticipate the impact of SI-BONE's recent clearance from the FDA for its improved iFuse Bedrock Granite Implant System.
This new system features a smaller diameter and expanded indications for pediatric patients and the S1 trajectory.
These advancements will likely contribute to the company's future performance and growth.

Despite the positive developments, SI-BONE's stock showed a decline of 2.33% in February 2024.
However, over the past 12 months, the stock has seen an overall increase of 16.49%. It is worth noting that SI-BONE's stock is currently trading 35.6% above its 52-week low, indicating the potential for further growth in the future.

Overall, SI-BONE's latest financial results demonstrate the company's commitment to improving its financial performance and driving revenue growth.
With the recent FDA clearance for its iFuse Bedrock Granite Implant System, SI-BONE is well-positioned for future success in the medical device industry.

Si Bone Inc's ROA

Si Bone Inc's ROA


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com